← Back to Search

Reflex Testing for POTS

N/A

Recruiting

Led By Marvin S Medow, Ph.D.

Research Sponsored by New York Medical College

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female POTS cases (N=80) aged 15-39 years, matched for BMI

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline in all subjects

Awards & highlights

Study Summary

This trial will investigate how women with POTS experience impaired blood and brain flow after standing, and how to help them with drugs.

Who is the study for?

This trial is for healthy women and those with Postural Tachycardia Syndrome (POTS) aged 15-39, matched by body weight. Participants must not have systemic diseases and should be able to stop taking any prescribed medications for at least two weeks before the study.Check my eligibility

What is being tested?

The study tests how blood pressure sensors (baroreflex) and oxygen sensors (chemoreflex) might cause POTS symptoms like rapid heartbeat when standing up. It involves chemoreflex testing, baroreflex testing, and orthostatic stress testing to understand these mechanisms in young women.See study design

What are the potential side effects?

Since this trial involves diagnostic tests rather than medication or invasive procedures, side effects are minimal but may include discomfort from the equipment used during testing or dizziness/light-headedness due to the orthostatic stress test.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman aged 15-39 with POTS, and my weight is similar to others in the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline in all subjects

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline in all subjects

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline in all subjects for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Effects of chemoreflex activation on baroreflexfunction and the effects of baroreflex on chemoreflex sensitivity

Measurement of chemoreflex sensitivity carotid body chemoreflex and central chemoreflex

Orthostasis Induced Depth of Breathing

+7 more

Secondary outcome measures

Systemic changes in abdominal blood volumes during orthostatic testing.

Systemic changes in leg blood volumes during orthostatic testing.

Trial Design

3Treatment groups

Active Control

Group I: Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapniaActive Control3 Interventions

Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.

Group II: Female POTS patients with orthostatic hyperpneic hypocapniaActive Control3 Interventions

Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.

Group III: Healthy Female vounteersActive Control3 Interventions

Healthy Female vounteers

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor

69 Previous Clinical Trials

6,031 Total Patients Enrolled

5 Trials studying Postural Orthostatic Tachycardia Syndrome

290 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome

Marvin S Medow, Ph.D.Principal InvestigatorNew York Medical College

Media Library

Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia Clinical Trial Eligibility Overview. Trial Name: NCT05923840 — N/A

Postural Orthostatic Tachycardia Syndrome Research Study Groups: Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia, Female POTS patients with orthostatic hyperpneic hypocapnia, Healthy Female vounteers

Postural Orthostatic Tachycardia Syndrome Clinical Trial 2023: Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia Highlights & Side Effects. Trial Name: NCT05923840 — N/A

Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia 2023 Treatment Timeline for Medical Study. Trial Name: NCT05923840 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for qualified participants to join this research endeavor?

"Affirmative. Per the information available on clinicaltrials.gov, this trial is presently recruiting participants. It was initially listed on September 23rd 2022 and has been updated most recently on June 20th 2023. To date, 30 individuals have signed up at one medical centre."

Answered by AI

How many participants are included in this experiment?

"Affirmative. Clinicaltrials.gov data implies that this trial is presently scouting for subjects, beginning from the initial posting date of September 23rd 2022 until June 20th 2023. The study requires 30 patients to be enrolled at one specific medical facility."

Answered by AI

Does this trial have an age restriction, and if so, what is the cutoff for participation?

"This clinical trial's enrolment is restricted to those aged 15-39. There are 384 trials that accommodate minors and 1087 for seniors respectively."

Answered by AI

Is there any possibility of me joining this medical study?

"To be considered for the trial, participants should present with hyperventilation and fall within a 15 to 39-year age range. Thus far, roughly 30 individuals have been enrolled in this study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia

Marvin Medow 2022. "Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05923840.